AI
The company said the AI integration has improved the biomarker detection of the Guardant cancer protein test by over 20%.
It plans to further expand across China's Greater Bay Area.
They seek to identify digital predictive biomarkers of narcolepsy and excessive daytime sleeping.
It seeks to raise the number of skin checks in Australia by a quarter.
It plans to secure more regulatory approvals for its AI pathology platform.
Also, AI cancer treatment software provider PVMed scores $14M in Series A funding.
Also, Lunit signed multiple contracts this week to deliver its AI imaging software in Hong Kong, Mongolia, and Brazil.
This follows its earlier approvals from the US, Europe, Japan and Taiwan.
The startup has set up a subsidiary in New York using the proceeds from its first Series C round.
EchoSolv accurately identifies patients with guideline-defined aortic stenosis using AI.